ICH Q4B Annex 9(R1): Tablet Friability Guide
ICH Q4B Annex 9(R1) explains the regulatory interchangeability of pharmacopoeial procedures for tablet friability. The current Step 4 version, dated 27 September 2010, recognises Ph. Eur. 2.9.7 Friability of Uncoated Tablets, JP General Information 26 Tablet Friability Test, and USP <1216> Tablet Friability as interchangeable in ICH regions. The Annex also gives a clear harmonised acceptance rule: for a single determination, mass loss should be not more than 1.0% unless the dossier specifies otherwise; when three determinations are performed, the mean mass loss should be not more than 1.0% unless otherwise specified in the dossier. This makes Annex 9 one of the more straightforward Q4B topics, but correct implementation still depends on regional Step 5 adoption, use of the current pharmacopoeial text, appropriate method suitability, and regulatory change control for existing products. For pharmaceutical QC laboratories, tablet manufacturing teams, QA, Regulatory Affairs, students, and auditors, Annex 9 provides a concise global framework for aligning friability testing across major pharmacopoeias.
What Is ICH Q4B Annex 9(R1)?
ICH Q4B Annex 9(R1) is titled Tablet Friability General Chapter. It is an ICH Harmonised Tripartite Guideline produced through the Q4B process. The current Step 4 version is dated 27 September 2010 and incorporates the Health Canada interchangeability statement.
The Annex was developed after the relevant pharmacopoeial texts were submitted by the Pharmacopoeial Discussion Group (PDG). Its purpose is regulatory: to confirm whether the officially published regional procedures can be used interchangeably and to identify the acceptance criteria that support that conclusion.
Annex 9 sits within the broader ICH Quality Guidelines framework and is particularly relevant to oral solid dosage forms and routine tablet quality control.
ICH Q4B Annex 9(R1) Document History
The document-history table in the guideline identifies three major milestones:
| Date | Milestone |
|---|---|
| 11 June 2009 | Step 2 approval and release for public consultation. |
| 29 October 2009 | Step 4 approval and recommendation for adoption by the three ICH regulatory bodies. |
| 27 September 2010 | Health Canada interchangeability statement integrated, creating the current R1 version. |
What Is Tablet Friability?
Practical QC definition: Tablet friability is a measure of a tablet's tendency to lose mass through abrasion, chipping, or mechanical stress during handling under the conditions of the applicable compendial test.
The Q4B Annex itself focuses on pharmacopoeial interchangeability rather than teaching the full mechanics of friability testing. In routine tablet manufacturing and QC, friability testing is used as a practical indicator of mechanical robustness, especially for uncoated tablets, and can help identify weaknesses related to formulation or compression.
Which Pharmacopoeial Friability Tests Are Interchangeable?
Annex 9(R1) identifies the following official texts as interchangeable in ICH regions:
| Pharmacopoeia | Chapter referenced in Annex 9(R1) | Topic |
|---|---|---|
| European Pharmacopoeia | Ph. Eur. 2.9.7 Friability of Uncoated Tablets | Tablet friability |
| JP | JP General Information 26 Tablet Friability Test | Tablet friability |
| USP | USP <1216> Tablet Friability | Tablet friability |
ICH Q4B Annex 9(R1) Acceptance Criteria
Annex 9 gives a clear mass-loss criterion for interchangeability:
This acceptance rule is one of the most useful parts of Annex 9 because it provides a harmonised benchmark for the three pharmacopoeial procedures while still allowing a product-specific dossier to specify another justified requirement.
One Determination vs Three Determinations
The Annex also explains how the criterion should be applied when three determinations are conducted:
| Testing approach | Q4B Annex 9(R1) acceptance criterion |
|---|---|
| Single determination | Mass loss should be not more than 1.0%, unless otherwise specified in the dossier. |
| Three determinations | The mean mass loss of the three determinations should be not more than 1.0%, unless otherwise specified in the dossier. |
How to Calculate Tablet Friability
In routine QC practice, friability is commonly expressed as percentage mass loss:
This formula is practical explanatory context rather than wording taken from the Q4B Annex. Laboratories should follow the current applicable pharmacopoeial procedure for sample preparation, test conditions, handling, and calculation details.
Why Tablet Friability Matters in Pharmaceutical Manufacturing
Friability testing provides a direct indication of whether tablets can tolerate ordinary mechanical stresses encountered during downstream handling. Excessive mass loss can point to insufficient tablet strength or formulation/manufacturing variability.
From a manufacturing perspective, friability results may be considered alongside compression force, tablet hardness, thickness, weight variation, coating or packaging performance, and other finished-product attributes. These relationships are practical pharmaceutical-development considerations rather than requirements created by Q4B Annex 9.
Regional Implementation: FDA, EU, MHLW, and Canada
| Region | Annex 9(R1) position | Practical implication |
|---|---|---|
| United States / FDA | The referenced texts can be considered interchangeable subject to Annex conditions. | FDA may still request that the chosen method be shown to be acceptable and suitable for the specific material or product. |
| European Union | A corresponding text from another pharmacopoeia may be accepted under the Annex conditions as fulfilling Ph. Eur. 2.9.7. | The interchangeable reference may be used in a marketing authorisation application, renewal, or variation. |
| Japan / MHLW | The referenced texts may be used as interchangeable. | Implementation details are provided through the applicable MHLW notification. |
| Canada | The R1 revision added the Health Canada interchangeability statement. | Any text cited in Section 2.1 can be considered interchangeable when used according to the Annex conditions. |
When Can ICH Q4B Annex 9(R1) Be Used?
Annex 9 states that it can be used in a region after it has been incorporated into that region's regulatory process at ICH Step 5. Implementation timing may differ by region.
The Q4B FAQ reinforces that regional implementation is the point at which stakeholders can begin relying on the listed official texts as interchangeable.
How Pharmaceutical Industry Should Implement Annex 9
For new registrations
The Q4B-evaluated pharmacopoeial text should be appropriately referenced in the application dossier. If the product uses an acceptance criterion other than the general 1.0% Q4B criterion, that product-specific requirement should be clearly reflected in the dossier.
For existing products
If an existing friability method is changed to another implemented Q4B-evaluated pharmacopoeial text, any notification, variation, and/or prior approval should follow the established regional mechanism for compendial changes.
For global QC strategy
The Q4B FAQ explains that interchangeable chapters are intended to reduce redundant testing. Where Annex 9 is implemented, a company can reference the accepted pharmacopoeial text rather than automatically maintaining separate equivalent friability methods for every region.
QC, Equipment, and Data-Integrity Considerations
Tablet friability testing should be controlled within the site's cGMP system and an approved SOP. The friability tester, balance, timer, and any associated records should be suitable for their intended use and controlled according to site procedures.
Where the site's lifecycle system applies, equipment qualification can be supported through documents such as URS, DQ, IQ, OQ, and PQ, as appropriate.
Initial mass, final mass, tablet observations, calculations, repeat determinations, and approvals should remain traceable under applicable ALCOA+ principles.
Practical Example: Single Determination
Suppose a tablet sample has an initial mass of 6.000 g and a final mass of 5.952 g. The mass loss is 0.048 g. Using the standard percentage-loss calculation, friability is 0.8%.
Under the general Q4B Annex 9 acceptance criterion, a 0.8% loss would be within the NMT 1.0% criterion, assuming the dossier does not specify a different requirement and the test was performed according to the applicable current pharmacopoeial chapter.
Practical Example: Three Determinations
If three valid determinations produce mass losses of 0.7%, 0.9%, and 1.1%, the mean is 0.9%. Annex 9 states that when three determinations are conducted, the mean loss of mass should be NMT 1.0% unless the dossier specifies otherwise.
This example illustrates why the Annex distinguishes between a single determination and a three-determination approach. Laboratories should still follow the current pharmacopoeial text and approved procedure for when and how determinations are performed.
Common Mistakes to Avoid
- Assuming the 1.0% value can never be changed. Annex 9 allows another criterion when it is specified in the dossier.
- Applying the single-determination rule to three determinations. For three determinations, Annex 9 specifies the mean loss.
- Using historical chapter editions without checking current pharmacopoeias. The Q4B FAQ recommends the current applicable text for ongoing compliance.
- Treating Q4B interchangeability as proof of product-specific suitability. FDA may still request suitability evidence.
- Changing a registered method without regulatory assessment. Notification, variation, or prior approval may still be required.
- Ignoring controlled documentation. Calculations, observations, equipment status, and repeat testing should remain traceable.
ICH Q4B Annex 9(R1) Implementation Checklist
- Confirm test scope. Verify that the product falls within the applicable tablet friability chapter.
- Identify the current compendial chapter. Review current Ph. Eur. 2.9.7, JP General Information 26, or USP <1216> as applicable.
- Verify regional Step 5 implementation. Check every target market separately.
- Confirm the dossier criterion. Determine whether the standard 1.0% criterion or another registered criterion applies.
- Identify the determination approach. Apply the correct single-determination or three-determination acceptance logic.
- Confirm equipment status. Ensure the friability tester and balance are suitable and controlled.
- Align the SOP and worksheet. Ensure the calculation method and acceptance logic match the registered strategy.
- Perform change control. Assess impacts on specifications, SOPs, training, registrations, and controlled records.
- Determine regulatory reporting. Identify notification, variation, or prior-approval requirements before changing an existing method.
- Maintain data integrity. Ensure all masses, observations, calculations, and approvals are attributable and traceable.
Key Takeaways
- ICH Q4B Annex 9(R1) covers the Tablet Friability General Chapter and is dated 27 September 2010.
- European Pharmacopoeia 2.9.7, JP General Information 26, and USP <1216> are recognised as interchangeable.
- For a single determination, mass loss should be NMT 1.0% unless otherwise specified in the dossier.
- For three determinations, the mean mass loss should be NMT 1.0% unless otherwise specified in the dossier.
- The Annex becomes usable in a region after implementation at ICH Step 5.
- FDA may still request product-specific demonstration of method suitability.
- Existing method changes remain subject to regional compendial-change mechanisms.
- The current applicable pharmacopoeial chapter should be used for ongoing compliance.
Conclusion
ICH Q4B Annex 9(R1) provides a clear regulatory framework for treating the designated European Pharmacopoeia, Japanese Pharmacopoeia, and USP tablet friability procedures as interchangeable. Compared with some other Q4B topics, the Annex is relatively simple because it contains a direct harmonised mass-loss criterion and few additional conditions.
For pharmaceutical companies, effective implementation still requires confirmation of regional Step 5 status, use of the current pharmacopoeial chapter, alignment with the registered dossier, correct application of the single- or three-determination acceptance rule, and proper cGMP change control. Used correctly, Annex 9 can streamline global friability testing while preserving product-specific regulatory control.
Frequently Asked Questions About ICH Q4B Annex 9(R1)
1. What is ICH Q4B Annex 9(R1)?
It is the Q4B topic-specific Annex addressing regulatory interchangeability of pharmacopoeial tablet friability procedures.
2. Which pharmacopoeial friability chapters are interchangeable?
The Annex identifies Ph. Eur. 2.9.7, JP General Information 26, and USP <1216> as interchangeable.
3. What is the Q4B acceptance criterion for a single friability determination?
Mass loss should be not more than 1.0%, unless otherwise specified in the dossier.
4. What is the criterion when three determinations are performed?
The mean loss of mass for the three determinations should be not more than 1.0%, unless otherwise specified in the dossier.
5. Can the dossier specify a different friability limit?
Yes. Annex 9 explicitly allows a different criterion where it is otherwise specified in the dossier.
6. When can Annex 9(R1) be used?
It can be used after it has been incorporated into the regional regulatory process at ICH Step 5.
7. Can FDA request additional method-suitability evidence?
Yes. FDA may request that the company demonstrate that the chosen method is acceptable and suitable for the specific material or product.
8. Does the EU accept corresponding JP or USP friability texts?
Annex 9 states that EU regulatory authorities can accept the corresponding referenced pharmacopoeial text, under the Annex conditions, as fulfilling Ph. Eur. 2.9.7 requirements.
9. Can an existing registered friability method be changed automatically?
No. Notification, variation, and/or prior approval should still follow established regional mechanisms for compendial changes.
10. Should historical pharmacopoeial editions listed in Annex 9 always be used?
No. The Q4B FAQ explains that the historical references provide context for the evaluation and that the most current applicable pharmacopoeial chapter should be used for ongoing compliance.
Editorial source note: This article is an original explanatory adaptation of ICH Q4B Annex 9(R1), Tablet Friability General Chapter, together with the ICH Q4B Frequently Asked Questions dated 26 April 2012. Practical QC and manufacturing explanations are included to improve usability and are clearly distinguished from source-derived requirements. This article does not replace the current pharmacopoeia, approved dossier, regional implementation requirements, or regulator guidance.
.webp)
: Tablet Friability Guide){kind=link}